(Q45399116)

English

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

scientific article published on 24 October 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

0 references

1 reference

based on heuristic

inferred from title

chronic hepatitis B

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

author name string

Pierre Vandepapelière

1

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

George K K Lau

2

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Geert Leroux-Roels

3

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Yves Horsmans

4

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Edward Gane

5

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Tawesak Tawandee

6

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Mohd Ismail bin Merican

7

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Khin Maung Win

8

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Christian Trepo

9

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Graham Cooksley

10

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Martine Wettendorff

11

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Therapeutic HBV Vaccine Group of Investigators

13

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

language of work or name

0 references

publication date

24 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

8585-8597

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Introduction to chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Management of hepatitis B: summary of a clinical research workshop

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Clinical trial results of new therapies for HBV: implications for treatment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

The maze of treatments for hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Pathobiology of acute and chronic hepatitis B virus infection: an introduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

based on heuristic

inferred from DOI database lookup

Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Quantity and quality of virus-specific CD8 cell response: relevance to the design of a therapeutic vaccine for chronic HBV infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Antiviral effect of adefovir in combination with a DNA vaccine in the duck hepatitis B virus infection model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Translation of immunological knowledge into better treatments of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Efficacy and limitations of a specific immunotherapy in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

The serology of chronic hepatitis B infection revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Functional implications of hepatitis B surface antigen (HBsAg) in the T cells of chronic HBV carriers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.09.072

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.09.072

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45399116&oldid=2076585223"